-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Valacyclovir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/124832-26-4.gif)
| Category | Herpes simplex Virus (HSV) |
| CAS | 124832-26-4 |
| Description | Valaciclovir is an antiviral drug used in the management of herpes simplex, herpes zoster, and herpes B. |
Product Information
| Synonyms | Valaciclovir; Valtrex |
| IUPAC Name | 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate |
| Molecular Weight | 324.34 |
| Molecular Formula | C13H20N6O4 |
| Canonical SMILES | CC(C)C(C(=O)OCCOCN1C=NC2=C1NC(=NC2=O)N)N |
| InChI | InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1 |
| InChIKey | HDOVUKNUBWVHOX-QMMMGPOBSA-N |
| Melting Point | 170-172 |
| Flash Point | 309.7°C |
| Purity | >98% |
| Density | 1.5±0.1 g/cm3 |
| Solubility | In Vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Application | Antiviral agents |
| Storage | Store at -20°C |
| Complexity | 483 |
| Exact Mass | 324.15460314 |
| Index Of Refraction | 1.673 |
| In Vitro | VACV uptake was concentration dependent and saturable with a Michaelis-Menten constant and maximum velocity of 1.64 +/- 0.06 mM and 23.34 +/- 0.36 nmol/mg protein/5 min, respectively. A very similar Km value was obtained in hPEPT1/CHO cells and in rat and rabbit tissues and Caco-2 cells, suggesting that hPEPT1 dominates the intestinal transport properties of VACV in vitro. |
| In Vivo | For treatment of a first episode of genital herpes, valacyclovir (1 g twice a day) is as effective as acyclovir (200 mg five times a day) when given for 10 days. For treating recurrences, valacyclovir is as effective as acyclovir (200 mg five times a day) with a treatment period of 5 days. |
| PSA | 151.14000 |
| Target | HSV infection, IC50 Value: 2.9 microg/ml (for HSV-1) |
| XLogP3-AA | -0.9 |
